IRIS
MONDELLO, Patrizia
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.666
EU - Europa 4.213
AS - Asia 2.307
SA - Sud America 767
Continente sconosciuto - Info sul continente non disponibili 382
AF - Africa 68
OC - Oceania 3
Totale 12.406
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.505
RU - Federazione Russa 1.792
SG - Singapore 999
BR - Brasile 646
CN - Cina 594
IE - Irlanda 532
SE - Svezia 407
IT - Italia 376
PL - Polonia 315
HK - Hong Kong 253
DE - Germania 210
GB - Regno Unito 138
VN - Vietnam 137
FI - Finlandia 125
UA - Ucraina 111
FR - Francia 96
CA - Canada 68
IN - India 62
BD - Bangladesh 56
MX - Messico 33
AR - Argentina 32
NL - Olanda 28
JP - Giappone 26
IQ - Iraq 25
ID - Indonesia 22
CO - Colombia 21
EC - Ecuador 21
BE - Belgio 20
TR - Turchia 18
UZ - Uzbekistan 17
ES - Italia 16
AT - Austria 15
JO - Giordania 14
MA - Marocco 13
PY - Paraguay 13
ZA - Sudafrica 13
JM - Giamaica 10
PK - Pakistan 10
KE - Kenya 9
TT - Trinidad e Tobago 9
GT - Guatemala 8
NI - Nicaragua 8
PE - Perù 8
VE - Venezuela 8
CL - Cile 7
CW - ???statistics.table.value.countryCode.CW??? 7
MY - Malesia 7
TH - Thailandia 7
AZ - Azerbaigian 6
IL - Israele 6
NP - Nepal 6
BO - Bolivia 5
CI - Costa d'Avorio 5
CR - Costa Rica 5
CZ - Repubblica Ceca 5
DZ - Algeria 5
HN - Honduras 5
TN - Tunisia 5
UY - Uruguay 5
AM - Armenia 4
IR - Iran 4
LB - Libano 4
OM - Oman 4
PA - Panama 4
PH - Filippine 4
SA - Arabia Saudita 4
SC - Seychelles 4
SV - El Salvador 4
AL - Albania 3
DK - Danimarca 3
DO - Repubblica Dominicana 3
EE - Estonia 3
EG - Egitto 3
KG - Kirghizistan 3
LT - Lituania 3
PS - Palestinian Territory 3
RO - Romania 3
XK - ???statistics.table.value.countryCode.XK??? 3
AO - Angola 2
AU - Australia 2
BA - Bosnia-Erzegovina 2
ET - Etiopia 2
GE - Georgia 2
KW - Kuwait 2
NG - Nigeria 2
PR - Porto Rico 2
RS - Serbia 2
AE - Emirati Arabi Uniti 1
BB - Barbados 1
BG - Bulgaria 1
BH - Bahrain 1
BY - Bielorussia 1
CH - Svizzera 1
CM - Camerun 1
GP - Guadalupe 1
GY - Guiana 1
HR - Croazia 1
IS - Islanda 1
KZ - Kazakistan 1
LI - Liechtenstein 1
Totale 12.022
Salva come PNG Salva come JPEG
Città #
Ashburn 856
Singapore 577
Dublin 531
Moscow 522
Chandler 404
Dallas 329
Warsaw 315
San Jose 284
Hong Kong 252
Nyköping 239
Beijing 189
Council Bluffs 164
Jacksonville 162
Messina 152
Munich 127
Dearborn 98
Los Angeles 96
The Dalles 88
Princeton 84
Medford 73
New York 63
Des Moines 60
Ann Arbor 58
Lauterbourg 54
Lancaster 53
Cambridge 52
Helsinki 51
Houston 49
Santa Clara 44
São Paulo 42
Boardman 36
Wilmington 35
North Bergen 31
Redondo Beach 31
Ho Chi Minh City 29
Hanoi 28
Woodbridge 28
Buffalo 27
Seattle 27
Rome 26
Jinan 25
Rio de Janeiro 25
Dong Ket 24
Tianjin 24
San Mateo 23
Guangzhou 22
Shenyang 22
Chicago 20
Tokyo 20
Montreal 19
Orem 19
Brussels 18
Falls Church 18
Columbus 16
Milan 16
Phoenix 16
Turku 16
Atlanta 15
Baghdad 15
Belo Horizonte 15
Brasília 15
Nuremberg 15
Chennai 14
Jakarta 14
Tashkent 14
Brooklyn 13
Shenzhen 13
Amman 12
Nanchang 12
Nanjing 12
Ningbo 12
Amsterdam 11
Boston 10
Shanghai 10
Stockholm 10
Toronto 10
Frankfurt am Main 9
Lappeenranta 9
London 9
Porto Alegre 9
Washington 9
Curitiba 8
Haikou 8
Managua 8
Medellín 8
Mexico City 8
Pune 8
San Francisco 8
Zhengzhou 8
Campinas 7
Dhaka 7
Goiânia 7
Hangzhou 7
Hải Dương 7
Johannesburg 7
Kunming 7
Nairobi 7
Quito 7
Vienna 7
Willemstad 7
Totale 7.137
Salva come PNG Salva come JPEG
Nome #
Panobinostat acts synergistically with ibrutinib in diffuse large B cell lymphoma cells with MyD88 L265 mutations. 305
De novo mutation in SLC25A22 gene: expansion of the clinical and electroencephalographic phenotype 300
Bendamustine with Rituximab Is Safe and Effective As FRONT LINE Therapy in Elderly B-CLL Patients. an ITALIAN RETROSPECTIVE MULTICENTER Experience 244
Bortezomib, Thalidomide and Lenalidomide: Have They Really Changed the Outcome of Multiple Myeloma? 230
Apelin beyond kidney failure and hyponatremia: a useful biomarker for cancer disease progression evaluation 228
Cancer cachexia syndrome: pathogenesis, diagnosis, and new therapeutic options 224
90Y-Ibritumomab Tiuxetan consolidation after autologous stem cell transplantation improves survival of patients with intermediate-/high-risk diffuse large B-cell lymphoma not responding adequately to first-line treatment. 218
Interferon Alpha Has a Strong Anti-tumor Effect in Philadelphia-negative Myeloproliferative Neoplasms 207
90 Y-ibritumomab tiuxetan: A nearly forgotten opportunity 205
Should the Use of Surveillance Imaging in Diffuse Large B-Cell Lymphoma Be Discontinued? 203
Bendamustine in combination with rituximab for elderly patients with previously untreated B-cell chronic lymphocytic leukemia: A retrospective analysis of real-life practice in Italian hematology departments 192
Palmitoylethanolamide Reduces Early Renal Dysfunction and Injury Caused by Experimental Ischemia and Reperfusion in Mice. 188
Emerging markers of cachexia predict survival in cancer patients. 186
Efficacy of Intravenous Hydrocortisone Treatment in Refractory Neonatal Seizures: A Report on Three Cases 181
90Y-IBRITUMOMAB TIUXETAN CONSOLIDATION AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION IMPROVES SURVIVAL OF INTERMEDIATE/HIGH-RISK DIFFUSE LARGE B-CELL LYMPHOMA PATIENTS NOT RESPONDING ADEQUATELY TO FIRST 179
Kinase regulation of human MHC class i molecule expression on cancer cells 179
Biosimilar epoetin α is as effective as originator epoetin-α plus liposomal iron (Sideral®), vitamin B12 and folates in patients with refractory anemia: A retrospective real-life approach 178
Thyroid hormone autoantibodies: Are they a better marker to detect early thyroid damage in patients with hematologic cancers receiving tyrosine kinase inhibitor or immunoregulatory drug treatments? 174
Bone marrow micro-environment is a crucial player for myelomagenesis and disease progression. 173
Autoimmune hemolytic anemia during bendamustine plus rituximab treatment in CLL patients: multicenter experience 173
An immunogenic WT1-derived peptide that induces T cell response in the context of HLA-A*02:01 and HLA-A*24:02 molecules. 169
Congenital heart disease in down syndrome 169
Complications of trauma patients admitted to the ICU in level i academic trauma centers in the United States 168
90Y-Ibritumomab-Tiuxetan Consolidation Therapy for Advanced-Stage Mantle Cell Lymphoma After First-Line Autologous Stem Cell Transplantation: Is It Time for a Step Forward? 168
Relapsed or refractory extranodal DLBCL treated with lenalidomide: A single center study 160
STAT6 activation correlates with cerebrospinal fluid IL-4 and IL-10 and poor prognosis in primary central nervous system lymphoma 160
Thyroid function, autoimmunity and nodules in hematological malignancies 156
AUTOIMMUNE HAEMOLYTIC ANAEMIA DURING BENDAMUSTINE TREATMENT IN CLL PATIENTS 152
Selective inhibition of HDAC3 targets synthetic vulnerabilities and activates immune surveillance in lymphoma 150
The heart in Anderson-Fabry disease 150
BET Inhibition-Induced GSK3β Feedback Enhances Lymphoma Vulnerability to PI3K Inhibitors 147
Protective effect of apocynin, a NADPH-oxidase inhibitor, against contrast-induced nephropathy in the diabetic rats: a comparison with n-acetylcysteine. 142
Non-pegylated liposomal doxorubicin in lymphoma: patterns of toxicity and outcome in a large observational trial. 142
Glutamine-supplemented total parenteral nutrition improves immunological status in anorectic patients 141
A new mouse expressing human Fcγ receptors to better predict therapeutic efficacy of human anti-cancer antibodies 140
ABVD vs BEACOPP escalated in advanced-stage Hodgkin's lymphoma: Results from a multicenter European study 134
Characterization of immune exhaustion and suppression in the tumor microenvironment of splenic marginal zone lymphoma 133
Glutamine contributes to ameliorate inflammation after renal ischemia/reperfusion injury in rats 129
Is radiotherapy still necessary for diffuse large B-cell lymphoma therapy? 126
Primary diffuse large B-cell lymphoma of the bone: bendamustine and rituximab are able to overcome resistant disease. 125
Glutamine treatment attenuates the development of organ injury induced by zymosan administration in mice 124
Extranodal diffuse large B-cell lymphoma with monoclonal gammopathy: an aggressive and primary refractory disease responding to an immunomodulatory agent 124
Glutamine treatment attenuates the development of ischaemia/reperfusion injury of the gut. 123
Treatment of Aggressive B Cell Lymphomas: Updates in 2019 123
Frontline treatment of diffuse large B-cell lymphoma: Beyond R-CHOP 118
Necrotizing fasciitis as a rare complication of osteonecrosis of the jaw in a patient with multiple myeloma treated with lenalidomide: case report and review of the literature. 117
Thalidomide suppresses sclerosing encapsulating peritonitis in a rat experimental model 116
Phase II trial to investigate efficacy and safety of bendamustine, dexamethasone and thalidomide in relapsed or refractory multiple myeloma patients after treatment with lenalidomide and bortezomib 116
Bendamustine plus rituximab versus R-CHOP as first-line treatment for patients with indolent non-Hodgkin’s lymphoma: evidence from a multicenter, retrospective study 115
null 111
Effects of Apocynin, A Nadph-oxidase Inhibitor, In Contrast-induced Nephropathy 111
Circulating Mitotic Figures In A Patient With Dual Infection By Epstein-Barr Virus And Cytomegalovirus. 109
null 107
null 105
null 105
Primary central nervous system lymphoma: Novel precision therapies 99
null 99
PHASE II TRIAL TO INVESTIGATE EFFICACY AND SAFETY OF BENDAMUSTINE, DEXAMETHASONE AND THALIDOMIDE IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA PATIENTS AFTER TREATMENT WITH LENALIDOMIDE AND BORTEZOMIB 98
T-cell phenotype including CD57+ T follicular helper cells in the tumor microenvironment correlate with a poor outcome in follicular lymphoma 97
Insights into the tumor microenvironment of B cell lymphoma 97
null 96
null 95
Emerging drugs for diffuse large B-cell lymphoma. 94
null 93
Silencing GNAS enhances HDAC3i efficacy in CREBBP wild type B cell lymphoma 91
Bendamustine plus Rituximab Versus R-CHOP as First-Line Treatment for Patients with Follicular Lymphoma Grade 3A: Evidence from a Multicenter, Retrospective Study 90
null 90
Routine Use of Bendamustine in Patients with Chronic Lymphocytic Leukemia: An Observational Study 90
Prophylaxis with intrathecal or high-dose methotrexate in diffuse large B-cell lymphoma and high risk of CNS relapse 89
MicroRNA and long non-coding RNA analysis in IgM monoclonal gammopathies reveals epigenetic influence on cellular functions and oncogenesis 87
A diachronic-comparative analysis for the identification of the most powerful prognostic index for localized diffuse large B-cell lymphoma. 81
null 81
Tazemetostat: a treatment option for relapsed/refractory follicular lymphoma 81
null 79
Simplified risk stratification model for patients with Waldenström macroglobulinemia 76
null 75
PHOENIX rises: Genomic-based therapies for diffuse large B cell lymphoma 74
Pim kinases in hematological malignancies: where are we now and where are we going? 72
null 72
Biosimilar Erythropoietin Alpha Is Effective As Originator Erythropoietin Alpha Plus Liposomial Iron and B12 and Folates in Patients with Refractory Anemia: A Retrospective Real-Life Approach 71
Questionable Validity of Cardiac Risk Score on the Basis of the NSABP B-31 Model 68
null 67
null 66
null 64
Reshaping the therapeutic landscape of chronic lymphocytic leukaemia in the era of targeted therapy 60
Multiomic analysis identifies a high-risk signature that predicts early clinical failure in DLBCL 49
Efficacy and tolerability of bendamustine, bortezomib and dexamethasone in patients with relapsed-refractory multiple myeloma: a phase II study. 48
R-CHOP versus R-COMP: are they really equally effective? 46
null 46
Subsets of follicular lymphoma 3B have divergent outcomes: results from the prospective multicenter MER and LEO cohorts 43
Molecular Clusters and Tumor-Immune Drivers of IgM Monoclonal Gammopathies 41
null 41
Response to dasatinib in a patient with SQCC of the lung harboring a discoid-receptor-2 and synchronous chronic myelogenous leukemia. 40
Multi-omics analysis in IgM monoclonal gammopathies reveals epigenetic influence on oncogenesis via DNA methylation 36
Radiotherapy for stage I/II follicular lymphoma (FL): is it time for a re-appraisal? 36
null 35
Interim Positron Emission Tomography During Frontline Chemoimmunotherapy for Follicular Lymphoma 35
Inhibition of NF-κB DNA Binding Suppresses Myeloma Growth via Intracellular Redox and Tumor Microenvironment Modulation 34
null 33
RE-MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola-BR), CAR-T therapies, and lenalidomide/rituximab (R2) based on real-world data in patients with relapsed/refractory diffuse large B-cell lymphoma 32
Totale 11.939
Salva come PNG Salva come JPEG
Categoria #
all - tutte 41.487
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 41.487
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022474 0 0 0 0 30 19 20 19 8 104 66 208
2022/20231.490 136 128 85 119 91 141 14 80 628 18 37 13
2023/2024331 23 53 22 26 20 57 18 33 5 23 20 31
2024/20251.865 14 19 34 118 103 82 118 418 414 132 142 271
2025/20265.222 216 333 376 423 511 969 711 572 590 279 95 147
2026/20271.180 192 242 274 454 18 0 0 0 0 0 0 0
Totale 12.406